Targeted cleavage of rna using eukaryotic ribonuclease and external guide sequence
CA 2117903 C · Owner: Guerrier-Takada, Cecilia L. · Inventors: Altman, Sidney; Guerrier-Takada, Cecilia L.; Yuan, Yan
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
It has been discovered that any RNA can be targeted for cleavage by RNAase P from eukaryotic cells for example, human, HeLa cells, using a suitably designed oligoribonucleotide ("external guide sequence" or EGS) to form a hybrid with the target RNA, thereby creating a substrate for cleavage by RNAase P in vitro. There are two classes of EGS that can target RNA for cleavage human RNAase P. These are prepared by transcription from a small DNA fragment that contains a sequence coding for an RNA that can assume a tRNA-like secondary structure. In the first class the structure lacks at least the first thirteen nucleotides from the 5' terminus of the tRNA-like sequence the anticodon stem and …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 28, 1993 and granted January 12, 1999. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 28, 2013.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 28, 2015.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.